Drug Trial Radar · NCT07107945
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
135
Actual
Start
Dec 9, 2025
Primary completion
Apr 16, 2027
Study completion Apr 14, 2028
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Aug 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD. Other goals of the study are to find out how empagliflozin is tolerated and handled by the body in children and adolescents with CKD. Participants are put into 2 groups randomly, which means by chance. One group takes empagliflozin and the other group takes placebo. Placebo looks like empagliflozin but does not contain any medicine. Participants are twice as likely to be in the empagliflozin group. Participants take empagliflozin or placebo as tablets once a day for 6 months. After 6 months, participants in both groups take empagliflozin as tablets once a day for 1 year. Participants are in the study for a little over a year and a half. During this time, they visit the study site about 15 times and get at least 5 phone or video calls from the site staff. At the visits, the doctors take blood and urine samples from the participants. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Chronic Kidney Disease
Interventions
EmpagliflozinDrug
Empagliflozin
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Day 1 to the Week 24 visit in urine albumin-creatinine (UACR) [mg/g]Time frame: Up to week 24
- Change from Day 1 to the Week 24 visit in urine glucose [mmol/L]Time frame: Up to week 24
Locations
93 sites in 18 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Stanford University School of Medicine
Palo Alto, California
University of California Davis
Sacramento, California
University of California San Francisco
San Francisco, California
University of Miami
Miami, Florida
Emory University
Atlanta, Georgia
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Indiana University
Indianapolis, Indiana
Novak Center for Children's Health
Louisville, Kentucky
Johns Hopkins Hospital
Baltimore, Maryland
University of Michigan
Ann Arbor, Michigan
Children's Hospital of Michigan
Detroit, Michigan
M Health Fairview Masonic Children's Hospital
Minneapolis, Minnesota
Children's Mercy Hospitals and Clinics
Kansas City, Missouri
Hackensack University Medical Center
Hackensack, New Jersey
Jersey Shore University Medical Center
Neptune City, New Jersey
University of New Mexico
Albuquerque, New Mexico
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
Primary Children's Hospital
Salt Lake City, Utah
Virginia Commonwealth University Health Systems
Richmond, Virginia
Seattle Children's Hospital
Seattle, Washington
University of Wisconsin
Madison, Wisconsin
Hospital Italiano de Buenos Aires
CABA, Argentina
Hospital de Niños Dr. Ricardo Gutierrez
CABA, Argentina
Equipo Ciencia
CABA, Argentina
The Children's Hospital at Westmead
Westmead, New South Wales, Australia
Queensland Children's Hospital
South Brisbane, Queensland, Australia
Monash Children's Hospital
Clayton, Victoria, Australia
The Royal Children's Hospital
Parkville, Victoria, Australia
HUB CHU Brugmann
Brussels, Belgium
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
CHC Mont Legia
Liège, Belgium
University of Alberta Hospital (University of Alberta)
Edmonton, Alberta, Canada
BC Children's Hospital
Vancouver, British Columbia, Canada
The Hospital for Sick Children
Toronto, Ontario, Canada
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.